Overview

A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors

Status:
Not yet recruiting
Trial end date:
2026-09-13
Target enrollment:
Participant gender:
Summary
This is the first clinical trial of IDRX-42. The study is designed to evaluate the safety, tolerability, PK, and preliminary antitumor activity of IDRX-42 in adult participants with advanced (metastatic and/or surgically unresectable) GIST.
Phase:
Phase 1
Details
Lead Sponsor:
IDRx, Inc.